MAYWOOD, NJ (February, 2004) Nymox
Pharmaceutical Corporation (NASDAQ: NYMX) announced today that its TobacAlert
product has garnered attention from the press and news services around the world,
including in the U.S., Great Britain, France, Italy and Canada, following a January 19,
2004 story about TobacAlert by Avram Goldstein in the Washington Post and a
subsequent January 25 story by Charles Laurence in the Sunday Telegraph in London.
TobacAlert offers concerned individuals an accurate and cost-effective method of
determining whether a person has been exposed to second-hand smoke. TobacAlert is an
easy to use urine test that can be done at home and requires no instruments to use.
Both stories highlighted
TobacAlert's ability to detect second-hand smoke exposure. The reporter for the
Telegraph confirmed the effectiveness of the test by testing himself after two hours in a
smoky New York cigar club - the result: positive for second-hand smoke exposure.
TobacAlert allows people to
get answers about possible second-hand smoke exposure quickly, accurately and
easily, said Dr. Michael Munzar of Nymox. With the high level of concern
around the world about second-hand smoke, we are delighted to see the interest in a
revolutionary new product like TobacAlert.
TobacAlert retails for a suggested
retail price of $14.99 and is available in selected CVS Pharmacies and on-line through CVS
at www.cvs.com and through drugstore.com at www.drugstore.com. More information about
TobacAlert is available at www.tobacalert.com.